BIMO Warnings Increase In Fiscal 2000, Sponsor Monitoring Problems Fewer
This article was originally published in The Gray Sheet
Executive Summary
FDA's Center for Devices and Radiological Health bioresearch monitoring division (BIMO) issued 23 warning letters and 137 untitled letters as of August FY 2000, a roughly 27% increase in each category compared with the full 12-month period of FY 1999.
You may also be interested in...
CDRH Focuses Bioresearch Inspections On Sponsor Monitoring In FY 99
Inadequate monitoring of clinical trial sites was found in over 50% of inspections of device study sponsors in fiscal year 1999, Charma Konnor, director of the Division of Bioresearch Monitoring within the Center for Devices and Radiological Health told attendees at a Dec. 16 session of the Food & Drug Law Educational Conference in Washington, D.C.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.